Nerofe is under clinical development by Immune System Key and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nerofe’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nerofe is under development for the treatment of advanced malignancies, solid tumors, pancreatic cancer, myelodysplastic syndrome, Alzheimer''s disease and relapsed and refractory acute myelocytic leukemia (AML). The drug candidate is administered by intravenous route as an infusion. It is a derivative of the human hormone-peptide tumor-cells apoptosis factor (TCApF). It contains 14 amino-acids. The drug candidate acts by targeting IL1RL1. It was under development for the treatment of renal cell carcinoma, metastatic ovarian cancer, triple negative breast cancer, metastatic colorectal carcinoma.
Immune System Key overview
Immune System Key (ISK) is a drug discovery and development company. It offers treatments for malignant and autoimmune diseases with unmet needs. The company provides lead compound such as Nerofe, the US Food and Drug Administration approved orphan drug for the treatment of AML. In addition, It also offers assets which are based on human secreted peptides. ISK provides Nerofe which is in preparation for phase IIa. ISK has several peptides and derivatives of natural human proteins which possess anti-cancer properties and the ability to regenerate several types of white blood cells. The company holds various patents on the molecule and applications. ISK is headquartered in Jerusalem, Israel.
For a complete picture of Nerofe’s drug-specific PTSR and LoA scores, buy the report here.